To appraise the clinical and cost effectiveness of durvalumab within its marketing authorisation for treating extensive stage small-cell lung cancer
 
Status In progress
Process STA 2018
ID number 1618

Provisional Schedule

Expected publication 16 December 2020

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
19 December 2019 Following on from advice received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early February 2020. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
16 August 2019 - 16 September 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
09 May 2019 In progress, Referred 29 April 2019

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance